Market Overview - The Shanghai Composite Index rose by 0.12% on July 28, with 15 sectors experiencing gains, led by defense and non-bank financials, which increased by 1.86% and 1.51% respectively. The pharmaceutical and biological sector ranked third in terms of gains [1] - Conversely, the coal and steel sectors saw declines of 2.60% and 1.41% respectively [1] Fund Flow Analysis - The main funds in the two markets experienced a net outflow of 18.575 billion yuan, with 8 sectors seeing net inflows. The electronics sector led with a net inflow of 3.655 billion yuan and a daily increase of 1.10%, followed by the communications sector with a net inflow of 2.848 billion yuan and a daily increase of 1.24% [1] - In contrast, 23 sectors faced net outflows, with the computer sector leading at a net outflow of 6.892 billion yuan, followed by the non-ferrous metals sector with a net outflow of 3.254 billion yuan [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector increased by 1.47% with a net inflow of 314 million yuan. Out of 474 stocks in this sector, 265 rose, 9 hit the daily limit up, while 191 fell, with 2 hitting the daily limit down [2] - Notably, 178 stocks in this sector experienced net inflows, with 8 stocks seeing inflows exceeding 100 million yuan. The top stock for net inflow was Heng Rui Medicine, with an inflow of 1.256 billion yuan, followed by Lu Kang Medicine and Zhong Sheng Pharmaceutical with inflows of 181 million yuan and 169 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Heng Rui Medicine: +10.00% with a turnover rate of 2.56% and a main fund flow of 1.255 billion yuan - Lu Kang Medicine: +4.30% with a turnover rate of 15.05% and a main fund flow of 181 million yuan - Zhong Sheng Pharmaceutical: +7.88% with a turnover rate of 11.59% and a main fund flow of 169 million yuan [3] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Changshan Pharmaceutical: -0.28% with a main fund outflow of 122.818 million yuan - Shenzhou Cell: -1.14% with a main fund outflow of 102.235 million yuan - WuXi AppTec: +3.08% with a main fund outflow of 94.187 million yuan [4]

证券代码：300255 证券简称：常山药业 公告编号：2025-31 河北常山生化药业股份有限公司（以下简称"公司"）于 2025 年 5 月 19 日 召开的 2024 年度股东大会审议并通过《关于提供担保额度预计的议案》，同意公 司为全资子公司河北常山凯库得生物技术有限公司（以下简称"凯库得"）借款 融资提供不超过 3.6 亿元的担保额度，上述额度期限自股东大会审议通过之日起 至 2025 年度股东大会之日。具体内容详见公司刊登于巨潮资讯网的《关于提供 担保额度预计的公告》（公告编号：2025-14）。 二、担保进展 2025 年 7 月 21 日，公司与中国农业银行股份有限公司正定县支行（以下简 称"农业银行"）签订了《保证合同》，公司为凯库得与农业银行签订的固定资 产借款合同下 772.2 万元的本金及利息提供连带责任保证。 本次担保事项在已经审议的年度担保额度范围内，无需再提交公司董事会或 股东大会审议。 河北常山生化药业股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 | | | | ...

证券代码：300255 证券简称：常山药业 公告编号：2025-30 河北常山生化药业股份有限公司 关于为公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 河北常山生化药业股份有限公司（以下简称"公司"、"母公司"）于 2025 年 5 月 19 日召开的 2024 年度股东大会审议并通过《关于提供担保额度预计的议 案》，同意全资子公司常山生化药业（江苏）有限公司（以下简称"江苏子公司"） 为母公司借款融资提供不超过 10.4 亿元的担保额度，同意全资子公司河北常山 凯库得生物技术有限公司（以下简称"凯库得"）为母公司借款融资提供不超过 6.4 亿元的担保额度，上述额度期限自股东大会审议通过之日起至 2025 年度股东 大会之日。具体内容详见公司刊登于巨潮资讯网的《关于提供担保额度预计的公 告》（公告编号：2025-14）。 二、担保进展 2025 年 7 月 18 日，江苏子公司与邯郸银行股份有限公司石家庄分行（以下 简称"邯郸银行"）签订了《保证合同》，江苏子公司为公司与邯郸银行签署的 《流动资金借款合同》（编号：J ...

Group 1: ExxonMobil Huizhou Ethylene Project - The ExxonMobil Huizhou Ethylene Project Phase I officially commenced production on July 15, with a total investment of $10 billion, marking it as the first major petrochemical project wholly owned by a U.S. company in China and the first foreign-funded petrochemical project in the Guangdong-Hong Kong-Macao Greater Bay Area [1][2] - Ethylene, known as the "mother of the petrochemical industry," is a crucial raw material for organic chemicals, and the project aims to produce high-end chemical products to effectively meet domestic market demand [1] Group 2: XPeng Heavens' B Round Financing - XPeng Heavens announced the completion of a $250 million B round financing on July 15, which will be used to ensure the smooth progress of research and development, mass production, and commercialization of flying cars [3] - The world's first flying car mass production factory has been topped out and is currently undergoing equipment debugging, with plans to be completed in the fourth quarter of this year, and the "land aircraft carrier" is expected to be delivered in 2026 [3][4] Group 3: Guangdong's Innovative Drug Approvals - Guangdong has received approval from the National Medical Products Administration for 25 Class I innovative drugs and 48 innovative medical devices, showcasing products like Ivosidenib injection and Orelabrutinib tablets [5] - The province ranks among the top in the country in terms of the number of pharmaceutical, medical device, and cosmetic manufacturing enterprises, as well as the quantity of registered products and innovative approvals [5][6] Group 4: Macao Tourism Price Index - The Macao tourism price index increased by 1.42% year-on-year in the second quarter of 2025, driven by higher prices for jewelry, watches, and entertainment, while clothing and dining services saw price declines [7] - The price index for miscellaneous items (jewelry, watches, and crafts) and entertainment and cultural activities rose by 13.40% and 12.00% respectively, while clothing and dining prices fell by 3.14% and 2.80% [7] Group 5: Shenzhen Stock Market Performance - The Shenzhen Component Index closed at 10,744.56 points, up 0.56% on July 15 [8] - Notable gainers included Dingjie Zhishi with a price of 46.02 yuan, up 20.00%, and Xinyi Sheng at 157.08 yuan, also up 20.00% [8]

Core Viewpoint - The innovation drug sector is experiencing positive developments with the official launch of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory and the Commercial Health Insurance Innovation Drug Directory adjustment [1][4]. Group 1: Policy Changes - The National Healthcare Security Administration (NHSA) has initiated the adjustment of the drug directories, allowing eligible applicants to submit online applications from July 11 to July 20 [4]. - The newly added commercial health insurance innovation drug directory focuses on high innovation, significant clinical value, and substantial patient benefits, which cannot be included in the basic directory due to exceeding the "basic protection" scope [4][5]. - The NHSA has released a series of documents outlining the adjustment work plan, including guidelines for the new commercial health insurance innovation drug directory [2][4]. Group 2: Market Reactions - The innovation drug sector has shown strong performance in the secondary market, with the Wind Innovation Drug Index rising over 2% on July 11, and several companies like Yifang Bio and Changshan Pharmaceutical seeing significant stock price increases [3][4]. - Multiple brokerages express optimism about the innovation drug sector and its related industrial chain, indicating a positive outlook for future investments [3][6]. Group 3: Institutional Support - The NHSA and the National Health Commission have issued measures to support high-quality development of innovation drugs, encouraging the use of healthcare data for drug research and promoting investment in innovation drugs by commercial health insurance [6][7]. - The measures also propose the establishment of a commercial health insurance innovation drug directory, which will include drugs that exceed basic insurance coverage but have high innovation and clinical value [6][7]. Group 4: Industry Growth Potential - Analysts highlight that the innovation drug sector has maintained rapid growth in product revenue and external licensing over the past three years, with significant business development (BD) transactions occurring this year [7][8]. - The increasing international competitiveness of Chinese innovation drug assets is noted, with clinical data gaining prominence at academic conferences and BD transactions on the rise [8][9].

Group 1: Innovation Drug Sector - The innovation drug concept is experiencing a resurgence, with Kangchen Pharmaceutical hitting the daily limit up [3] - Other companies in the sector such as Changshan Pharmaceutical and Boteng Co. saw increases exceeding 10% [3] - The overall market sentiment is positive, with the A-share market showing slight gains [1][2] Group 2: Stablecoin Concept - The stablecoin concept is also seeing significant gains, with Guoao Technology reaching a daily limit up of 20% [3] - Other companies like Geer Software and Greenland Holdings also hit their daily limits [3] - The Shanghai Municipal State-owned Assets Supervision and Administration Commission is focusing on the development trends of cryptocurrencies and stablecoins [3] Group 3: Real Estate Sector - The real estate sector is showing strong performance, with companies like Yucheng Development achieving five consecutive limit ups [4] - Policies to stabilize the housing market are being implemented, with over 150 measures introduced to optimize housing provident fund policies [4] - Other real estate companies such as Tianbao Infrastructure and Greenland Holdings also saw significant gains [4] Group 4: Pork Sector - The pork sector is experiencing notable activity, with Zhenghong Technology hitting the daily limit up [5] - Other companies like Dongrui Co. and Muyuan Foods are also among the top gainers in this sector [5]

Core Viewpoint - The innovative drug concept continues to show strong performance, with significant stock price increases for companies such as Boteng Co. and Changshan Pharmaceutical, which rose over 15% [1] Group 1: Stock Performance - Boteng Co. and Changshan Pharmaceutical saw stock increases of over 15% [1] - WuXi AppTec experienced a nearly 9% rise [1] - Other companies like Kylin Pharmaceutical, Guangsheng Pharmaceutical, and Yifang Bio also saw stock increases of over 5% [1] Group 2: Policy Announcement - On July 10, the National Healthcare Security Administration announced the adjustment plan for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogs, as well as the Commercial Health Insurance Innovative Drug Catalog [1] - The plan specifies that the adjustments to the basic medical insurance drug catalog and the establishment of the commercial health insurance innovative drug catalog will occur simultaneously in 2025 [1]

Core Points - The total margin financing balance of the ChiNext market reached 362.43 billion yuan, marking an increase for three consecutive trading days, with a cumulative increase of 3.22 billion yuan during this period [1][2] - As of July 9, 2025, the total margin balance was 363.52 billion yuan, reflecting an increase of 0.88 billion yuan from the previous trading day [2] Margin Financing Changes - The margin financing balance increased for 513 stocks, with 38 stocks experiencing an increase of over 20%. The stock with the highest increase was Jia Lian Technology, with a financing balance of 50.72 million yuan, showing a growth of 152.21% [2][3] - Conversely, 420 stocks saw a decrease in their financing balance, with 37 stocks declining by more than 10%. The largest decrease was observed in Yitong New Materials, with a financing balance of 65.98 million yuan, down by 30.43% [2][3] Market Performance - Among stocks with a financing balance increase of over 20%, the average increase was 9.77%, outperforming the ChiNext index. The top gainers included Tongguan Copper Foil, Suwen Electric, and Jia Lian Technology, with increases of 51.42%, 31.68%, and 30.09%, respectively [5] - The stocks with the largest increase in financing balance included Mindray Medical, with a balance of 2.704 billion yuan, increasing by 346 million yuan, followed by Shenghong Technology and Changliang Technology, with increases of 303 million yuan and 234 million yuan, respectively [5][6]

Group 1 - The core point of the article highlights the net inflow of main funds into various industries, with a total of 65.68 billion yuan flowing into the Shanghai and Shenzhen markets on July 8, including 59.68 billion yuan into the ChiNext market and 57.92 billion yuan into the CSI 300 index [2] - Among the 13 industries with net inflows, the electronics industry led with a net inflow of 40.76 billion yuan, followed by the computer industry with 26.6 billion yuan, and the communication, power equipment, and non-bank financial industries each exceeding 16 billion yuan [2] - In contrast, 18 industries experienced net outflows, with the pharmaceutical and biological industry seeing the largest outflow of over 15 billion yuan, followed by public utilities, national defense, and basic chemicals, each with outflows exceeding 5 billion yuan [3] Group 2 - A total of 77 stocks had net inflows exceeding 1 billion yuan, with 9 stocks seeing inflows over 4 billion yuan. Zhongyou Capital topped the list with a net inflow of 9.01 billion yuan, closing at the daily limit [4] - Pengding Holdings ranked second with a net inflow of 6.41 billion yuan, while other notable stocks with significant inflows included Zhongji Xuchuang, N Yitang, Dongfang Caifu, and Inspur Information, with inflows of 5.85 billion yuan, 5.16 billion yuan, 5.16 billion yuan, and 4.86 billion yuan respectively [6] - On the other hand, 37 stocks had net outflows exceeding 1 billion yuan, with Changshan Pharmaceutical leading the outflow at 8.3 billion yuan, followed by Jinyi Culture, Rongfa Nuclear Power, and Shaoneng Shares [7][8] Group 3 - At the end of the trading day, there was a net inflow of 35.8 billion yuan, with the ChiNext market contributing 12.97 billion yuan and the CSI 300 index contributing 13.24 billion yuan [9] - Among the stocks with significant end-of-day inflows, Dongfang Caifu led with a net inflow of 2.21 billion yuan, followed by Hangang Co., Zhongzhou Special Materials, and Ningde Times [10][11] - Conversely, 7 stocks experienced end-of-day net outflows exceeding 0.6 billion yuan, with Changshan Pharmaceutical again leading with a net outflow of 1.65 billion yuan, closing down 12.8% [12]

Market Overview - The net inflow of large orders in the two markets reached 17.109 billion yuan, with 38 stocks seeing net inflows exceeding 200 million yuan, led by Zhongyou Capital with a net inflow of 999 million yuan [1][2] - The Shanghai Composite Index closed up by 0.70% today, with a total of 2,292 stocks experiencing net inflows and 2,442 stocks seeing net outflows [1] Industry Performance - Among the 15 industries with net inflows, the electronics sector had the highest net inflow of 5.568 billion yuan, with an index increase of 2.27%. The power equipment sector followed with a net inflow of 3.721 billion yuan and a rise of 2.30% [1] - The industries with net outflows included public utilities, which saw the largest outflow of 1.185 billion yuan, followed by the pharmaceutical and biological sector with an outflow of 1.147 billion yuan [1] Individual Stock Performance - The top stocks with net inflows exceeding 200 million yuan included Zhongyou Capital (999 million yuan), Industrial Fulian (990 million yuan), and Hangang Co. (889 million yuan). These stocks averaged a rise of 13.10%, outperforming the Shanghai Composite Index [2][3] - Stocks with the largest net outflows included Changshan Pharmaceutical (-718 million yuan), Huagong Technology (-382 million yuan), and Jinyi Culture (-357 million yuan) [2][3] Detailed Stock Data - The top stocks with significant net inflows are as follows: - Zhongyou Capital: 8.65 yuan, +10.05%, 999 million yuan, Non-bank Financial [2] - Industrial Fulian: 26.38 yuan, +10.01%, 990 million yuan, Electronics [2] - Hangang Co.: 9.58 yuan, +9.99%, 889 million yuan, Steel [2] - The stocks with the largest net outflows are: - Changshan Pharmaceutical: 40.52 yuan, -12.80%, -718 million yuan, Pharmaceutical [3] - Huagong Technology: 44.93 yuan, +1.03%, -382 million yuan, Machinery [3] - Jinyi Culture: 4.75 yuan, +7.47%, -357 million yuan, Textile and Apparel [3]